Welcome to our annual celebration of the great and inspirational minds that contribute to the development and manufacture of new medicinal products
The Power List 2022 focuses on the top 10 VIPs in three key categories of medicine making
Sitting Down With... Ajaz Hussain, President, National Institute for Pharmaceutical Technology and Education, Minnesota, USA.
Biosimilars had their big break in the US in 2015, but three years later biosimilars are still struggling to make a mark.
Sitting Down With Cyrus Krakaria, President of Biotechnology for Lupin Limited, Biotech Division, India.
WHO is investigating the potential of certain biosimilars in a prequalification pilot program.
Initially, The American College of Rheumatology was cautious about biosimilars, but times have changed.
The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.
Why does the full potential of biosimilars remain untapped? Four experts weigh in.
The latest business news and views in pharma.
Why is the pharma industry overly reluctant to accept new ideas?
FDA Commissioner Scott Gottlieb wants more biosimilars on the US market.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.
Every Disease Has its Day
The Cutting Edge of Biopharma Analytics
It’s All About Connecting